Breast Cancer Clinical Trials in Baltimore, MD

Breast Cancer Clinical Trials in Baltimore, MD

View the best 10 breast cancer medical studies in Baltimore, Maryland. Access promising new therapies by applying to a Baltimore-based Breast Cancer clinical trial.

Trials in Baltimore, Maryland

Here are the top 10 medical studies for breast cancer in Baltimore, Maryland

Image of St. Joseph's Hospital and Medical Center in Phoenix, United States.

Abemaciclib +1 More

CDK4/6 Inhibitor

Recruiting1 awardPhase 3
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Image of Sibley Memorial Hospital in Washington, United States.

Cognitive-Behavioral Therapy for Insomnia (CBT-I) +1 More

Behavioural Intervention

Recruiting0 awards13 criteria
This trial will compare two treatments for overweight/obese women with early stage breast cancer and insomnia: one with an insomnia intervention before weight loss, and one with sleep education before weight loss. Outcomes will be measured at various time points.
Image of Site 3 in Nashville, United States.

Nivolumab +2 More

Monoclonal Antibodies

Recruiting2 awardsPhase 1
This trial is testing a new drug called XB002, given through an IV periodically, to see if it can help patients with advanced solid tumors. The drug is tested alone and with other cancer treatments. Researchers are checking if it is safe and effective in shrinking or stopping tumor growth.
Image of Johns Hopkins in Baltimore, United States.

Niraparib +2 More

PARP Inhibitor

Recruiting1 awardPhase 2
This trial will test to see if the addition of Dostarlimab and Niraparib to Radiation Therapy will be safe and effective in treating participants with metastatic triple negative breast cancer.
Image of Research Site in Phoenix, United States.

AZD9833 +2 More

Selective Estrogen Receptor Degrader (SERD)

Recruiting1 awardPhase 3
This trial is testing whether a new combination therapy is better than the current standard of care for treating a certain type of breast cancer.
Image of Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028) in Marietta, United States.

Pembrolizumab +3 More

Monoclonal Antibodies

Recruiting2 awardsPhase 3
This trial will assess if pembrolizumab, when combined with chemotherapy, is more effective in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer than chemotherapy alone. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.
Image of START Midwest, LLC in Grand Rapids, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
Image of CBCC Global Research Inc., at Comprehensive Blood and Cancer Center in Bakersfield, United States.

Giredestrant +1 More

Selective Estrogen Receptor Degrader (SERD)

Recruiting2 awardsPhase 3
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Image of Carle Cancer Center in Urbana, United States.

Ribociclib +1 More

CDK4/6 Inhibitor

Recruiting4 awardsPhase 3
This trial will compare two treatments to find out which is better at prolonging progression-free survival in patients with advanced HER2-E and HR+/HER2- breast cancer.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

ARX788

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.